STADA Arzneimittel AG (SAZ) Given Consensus Rating of “Sell” by Brokerages
Shares of STADA Arzneimittel AG (ETR:SAZ) have been assigned an average recommendation of “Sell” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating and two have issued a hold rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is €69.07 ($82.23).
A number of brokerages have recently issued reports on SAZ. Independent Research GmbH set a €76.00 ($90.48) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Tuesday, September 5th. Warburg Research set a €74.40 ($88.57) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Tuesday, September 5th. Nord/LB set a €65.53 ($78.01) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Thursday, August 31st. Commerzbank Ag set a €66.25 ($78.87) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Tuesday, August 22nd. Finally, S&P Global set a €66.25 ($78.87) price target on STADA Arzneimittel AG and gave the company a “neutral” rating in a report on Thursday, August 3rd.
Shares of STADA Arzneimittel AG (SAZ) opened at 80.584 on Monday. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €84.20. The firm has a market cap of €5.02 billion and a P/E ratio of 53.261. The firm’s 50-day moving average is €74.04 and its 200-day moving average is €65.54.
TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/24/stada-arzneimittel-ag-saz-given-consensus-rating-of-sell-by-brokerages.html.
About STADA Arzneimittel AG
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.